2025-04-25 - Analysis Report
## Eli Lilly and Co (LLY) Stock Report

**0) Executive Summary:**

Eli Lilly and Co (LLY) is a leading pharmaceutical company.  This report analyzes LLY's performance against the S&P 500 (VOO), considering its recent price movements, financial indicators, and earnings data.  LLY demonstrates significant outperformance relative to the S&P 500, although volatility should be considered.


**1) Performance Comparison:**

* **LLY Cumulative Return:** 322.13%
* **VOO (S&P 500) Cumulative Return:** 82.57%
* **Return Difference:** 239.6%  This indicates a substantial outperformance of LLY compared to the S&P 500.  The relative divergence (72.9%) suggests LLY's performance is significantly above the historical range compared to the S&P 500.


**Alpha and Beta Analysis:**

The provided data shows strong and consistently positive alpha values over the years, ranging from 0.1 to 1.4, suggesting consistent outperformance compared to the market. Beta values are high, ranging from 67.7 to 692, indicating high market sensitivity.  However, the high CAGR (Compound Annual Growth Rate) numbers further underscore strong growth potential.  Note that the increasing beta values and large market cap over the years might suggest a larger correlation with the market's overall trend.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 14.0% | 55.9% | -19.0% | 0.1 | 67.7 |
| 2016-2018  | 42.0% | 58.6% | 21.0% | 0.1 | 95.1 |
| 2017-2019  | 55.0% | 58.6% | 21.0% | 1.4 | 110.4 |
| 2018-2020  | 57.0% | 58.6% | 27.0% | 0.7 | 144.7 |
| 2019-2021  | 116.0% | 60.5% | 55.0% | 0.4 | 240.3 |
| 2020-2022  | 111.0% | 64.9% | 102.0% | 0.3 | 322.6 |
| 2021-2023  | 152.0% | 64.9% | 132.0% | 0.3 | 519.2 |
| 2022-2024  | 171.0% | 72.1% | 150.0% | 0.3 | 692.0 |
| 2023-2025  | 154.0% | 76.8% | 133.0% | 0.2 | 772.0 |


**2) Recent Price Movement:**

* **Closing Price:** $859.73
* **5-Day Moving Average:** $834.93
* **20-Day Moving Average:** $784.95
* **60-Day Moving Average:** $833.62

The price is above all three moving averages, suggesting a short-term uptrend.  The recent price change of $3.65 (Last-market data) indicates a sharp increase.


**3) Technical Indicators:**

* **Market Risk Indicator (MRI):** 0.4053 (Medium Risk)
* **RSI:** 59.94 (Approaching overbought territory, but not yet signaling a reversal.)
* **PPO:** 1.75 (Positive, indicating bullish momentum.)
* **20-Day Relative Divergence Change:** +4.1 (Short-term upward trend)
* **Expected Return (vs. S&P 500):** 76.3% over the long term (2+ years). This high expected return supports the argument for long term investment.


**4) Recent Earnings Analysis:**

The earnings data shows significant volatility.  While Q2 2024 showed strong EPS and revenue, other quarters show considerable fluctuations.  Further investigation is needed to understand the drivers of this variability.

| Date       | EPS    | Revenue       |
|------------|--------|---------------|
| 2024-10-30 | $1.08  | $11.44B       |
| 2024-08-08 | $3.29  | $11.30B       |
| 2024-04-30 | $2.49  | $8.77B        |
| 2023-11-02 | -$0.06 | $9.50B        |
| 2024-10-30 | -$0.06 | $9.50B        | *(Note: Duplicate entry, likely a data error)*


**5) Financial Information:**

Revenue growth is consistent, with high profit margins consistently above 80%.  ROE (Return on Equity) shows some volatility but generally indicates strong profitability.  Further analysis would be required to examine the underlying factors contributing to these financial metrics.

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $13.53B | 82.24% |
| 2024-09-30 | $11.44B | 81.02% |
| 2024-06-30 | $11.30B | 80.80% |
| 2024-03-31 | $8.77B | 80.91% |
| 2023-12-31 | $9.35B | 80.88% |

**Capital and Profitability:**

| Quarter | Equity    | ROE       |
|---------|-----------|------------|
| 2024-12-31 | $14.19B  | 31.07%     |
| 2024-09-30 | $14.24B  | 6.81%      |
| 2024-06-30 | $13.56B  | 21.88%     |
| 2024-03-31 | $12.81B  | 17.51%     |
| 2023-12-31 | $10.77B  | 20.33%     |


**6) Overall Analysis:**

LLY exhibits strong historical performance significantly outpacing the S&P 500.  While the recent price movement shows an upward trend,  the high beta suggests sensitivity to market fluctuations.  The strong CAGR and consistently positive alpha point to a strong investment case.  However, careful consideration should be given to the earnings volatility and the need for further investigation into the factors driving that volatility. The high expected return relative to the S&P 500 supports a long-term investment strategy, though potential increased risk from the high beta should be managed accordingly.  More detailed fundamental analysis of the company's business model and future prospects is recommended before making any investment decisions.
